Marybeth McCauley - Concepedia

Author

Marybeth McCauley

Also Known As

Berman, Richard, Chariyalertsak, Suwat, Chege, Wairimu, Cohen, Myron S., Fogel, Jessica M., Hakim, James G., Hoffman, Irving F., Kumarasamy, Nagalingeshwaran, Kumarasamy, Nagalingeswaran, M McCauley

Publications

12.1K

Citations

H-Index

Concepts

All Affiliations

Family Health International 360 Fred Hutch Cancer Center Johns Hopkins University University of North Carolina at Chapel Hill Johns Hopkins Medicine

About

Marybeth McCauley is an author at Family Health International 360 specializing in medicine, hiv, and sexual health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.1K
2	Public Health	5	5	287
3	Social Sciences	1	1	21
4	Biochemistry	1	1	17
5	Cell Biology	1	1	17

Marybeth McCauley

Publications

11.5K

Citations

H-Index

Page 1

	Year	Citations
Prevention of HIV-1 Infection with Early Antiretroviral Therapy Myron S. Cohen, Ying Qing Chen, Marybeth McCauley, New England Journal of Medicine	2011	6.9K
Antiretroviral Therapy for the Prevention of HIV-1 Transmission Myron S. Cohen, Ying Qing Chen, Marybeth McCauley, New England Journal of Medicine	2016	1.7K
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement, New England Journal of Medicine	2021	773
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial Beatriz Grinsztejn, Mina C. Hosseinipour, Heather J. Ribaudo, The Lancet Infectious Diseases Hptn 052Hiv/aids CounsellingTreatment And PreventionHuman RetrovirusAntiviral Therapy	2014	507
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial Raphael J. Landovitz, Sue Li, Beatriz Grinsztejn, PLoS Medicine	2018	164
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial Raphael J. Landovitz, Sue Li, Joseph J. Eron, The Lancet HIV Treatment And PreventionPharmacologyAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapy	2020	159
Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples Rochelle P. Walensky, Eric L. Ross, Nagalingeswaran Kumarasamy, New England Journal of Medicine	2013	136
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 Mark A. Marzinke, Beatriz Grinsztejn, Jessica M. Fogel, The Journal of Infectious Diseases	2021	120
Analysis of Genetic Linkage of HIV From Couples Enrolled in the HIV Prevention Trials Network 052 Trial Susan H. Eshleman, Sarah E. Hudelson, Andrew D. Redd, The Journal of Infectious Diseases	2011	109
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077 Elizabeth E. Tolley, Sahar Z. Zangeneh, Gordon Chau, AIDS and Behavior Hiv-uninfected IndividualsPharmacotherapyAntiviral DrugPreventive MedicineDaily Oral Prep	2020	90

Page 1